Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable
Crossref DOI link: https://doi.org/10.1007/s40267-020-00715-z
Published Online: 2020-02-25
Published Print: 2020-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
,
Text and Data Mining valid from 2020-02-25
Version of Record valid from 2020-02-25
Article History
First Online: 25 February 2020
Compliance with ethical standards
:
: The preparation of this review was not supported by any external funding.
: The authors declare no conflicts of interest.